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Abstract
Background: Chronic Fatigue Syndrome (CFS) studies from our laboratory and others have
described cytokine abnormalities. Other studies reported no difference between CFS and controls.
However, methodologies varied widely and few studies measured more than 4 or 5 cytokines.
Multiplex technology permits the determination of cytokines for a large panel of cytokines
simultaneously with high sensitivity and with only 30 ul of plasma per sample. No widely accepted
laboratory test or marker is available for the diagnosis or prognosis of CFS. This study screened
plasma factors to identify circulating biomarkers associated with CFS.
Methods: Cytokines were measured in plasma from female CFS cases and female healthy controls.
Multiplex technology provided profiles of 16 plasma factors including the pro -inflammatory
cytokines: tumor necrosis factor α (TNFα), lymphotoxin α (LTα), interleukin (IL) - IL-Iα, IL-1β, IL-
6; TH1 cytokines: interferon γ (IFNγ), IL-12p70, IL-2, IL-15; TH2: IL-4, IL-5; TH17 cytokines, IL-17
and IL-23; anti-inflammatory cytokines IL-10, IL-13; the inflammatory mediator and neutrophil
attracting chemokine IL-8 (CXCL8). Analysis by receiver operating characteristic (ROC) curve
assessed the biomarker potential of each cytokine.
Results: The following cytokines were elevated in CFS compared to controls: LTα, IL-1α, IL-1β,
IL-4, IL-5, IL-6 and IL-12. The following cytokines were decreased in CFS: IL-8, IL-13 and IL-15. The
following cytokines were not different: TNFα, IFNγ, IL-2, IL-10, IL-23 and IL-17. Applying (ROC)
curve analyses, areas under the curves (AUC) for IL-5 (0. 84), LTα (0.77), IL-4 (0.77), IL-12 (0.76)
indicated good biomarker potential. The AUC of IL-6 (0.73), IL-15 (0.73), IL-8 (0.69), IL-13 (0.68)
IL-1α (0.62), IL-1β (0.62) showed fair potential as biomarkers.
Conclusion: Cytokine abnormalities are common in CFS. In this study, 10 of 16 cytokines
examined showed good to fair promise as biomarkers. However, the cytokine changes observed
are likely to more indicative of immune activation and inflammation, rather than specific for CFS.
As such, they are targets for herapeutic strategies. Newer techniques allow evaluation of large
panels of cytokines in a cost effective fashion.
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According to a Centers for Disease Control (CDC) report
[1] the overall prevalence in the USA of Chronic Fatigue
Syndrome (CFS), is 235 per 100,000 persons (95% confi-
dence interval, 142-327 per 100,000 persons). Up to 80%
of those affected are women [2]. These individuals suffer
from severe fatigue that impairs daily activity, diminishes
quality of life for years and has no known cure [3]. CFS
represents an economic burden for society (e.g., high rates
of unemployment due to disability) and healthcare insti-
tutions [4]. Hypothetical initiating events for CFS include
infections, psychiatric trauma and exposure to toxins.
Many of the symptoms are inflammatory in nature (myal-
gia, arthralgia, sore throat, tender lymphadenopathy),
and have prompted a theory of infection induced illness
[5,6]. In 60 to 80% of published samples, CFS presents
with acute onset of illness, with systemic symptoms simi-
lar to influenza infection that do not subside [7]. These
observations have led to reports of associated microbial
infections or reactivation of latent viral infections [5,8-
13]. However, there is no consensus as to etiology.
There is a considerable literature describing immune dys-
function in CFS [14,15]. Elevation of pro-inflammatory
cytokines [16,17] and evidence of TH2 (T helper cell type
2) cytokine activation [15,18] were reported. Other stud-
ies reported no difference between CFS and controls.
However, methodologies varied widely and few studies
measured more than four or five cytokines. Lack of sensi-
tivity of standard ELISA (enzyme-linked immunosorbent
assay) technology limited use of plasma for the detection
of case/control differences.
Despite evidences of immunological and molecular medi-
ators, no individual marker or combination of markers
has been sufficiently associated with CFS to enable its use
as a biomarker for the diagnosis or management of CFS.
The goal of this study was to determine if, using new tech-
nology, plasma cytokines had sufficient sensitivity and
specificity to distinguish CFS cases from age-matched
healthy controls. Using a multiplex assay, 16 cytokines
(TH1, TH2, TH17, pro-inflammatory, anti-inflammatory)
were compared among cases and controls. Because of the
strong gender bias in CFS (80% female), only women
were included in the study.
Methods
Patients
Female CFS patients (n = 40; mean age 50) were from the
CFS and Related Disorders Clinic at the University of
Miami. A diagnosis of CFS was made using the Interna-
tional Case Definition [19,20]. Female healthy controls (n
= 59; mean age 53) were from a NIH funded study. All
subjects signed an informed consent approved by the
Institutional Review Board of the University of Miami. All
CFS study subjects had a SF-36 summary physical score
(PCS) below the 50th percentile, based on population
norms. Exclusion criteria for CFS included all of those
listed in the current Centers for Disease Control (CDC)
CFS case definition, including the listed psychiatric exclu-
sions, as clarified in the International CFS Working Group
[20]. All CFS subjects were assessed for psychiatric diagno-
sis at the time of recruitment with the Composite Interna-
tional Diagnostic Instrument [21]. Based on this
assessment, we excluded subjects with DSM IV diagnoses
for psychotic or melancholic depression, panic attacks,
substance dependency, or psychoses as well as any sub-
jects currently suicidal. We also excluded subjects with
Borderline or Antisocial Personality Disorder. Subjects
had no history of heart disease, COPD, malignancy, or
other systemic disorders that would be exclusionary, as
clarified by Reeves et al. [20]. Subjects were also excluded
for the following reasons: less than 18 yrs of age, active
smoking or alcohol history, history of significant inability
to keep scheduled clinic appointments in past.
Ethical Issues
This study was approved by the institutional review board
and all patients gave written, informed consent.
Blood Collection
Morning blood samples were collected into ethylene
diamine tetra acetic acid. Plasma was separated within 2
hours of collection and stored at -80°C until assayed.
Cytokine Array System
We measured 16 cytokines in plasma using Quansys rea-
gents and instrument (Quansys Biosciences, Logan,
Utah). The Quansys Imager, driven by an 8.4 megapixel
Canon 20D digital SLR camera, supports 96 well plate
based chemiluminescent imaging. The Q-Plex™ Human
Cytokine - Screen (16-plex) is a quantitative ELISA-based
test where sixteen distinct capture antibodies have been
absorbed to each well of a 96-well plate in a defined array.
Manipulation of the range of the standard curves and
exposure time allowed reliable co mparisons between CFS
patients and controls of both low and high level cytokine
concentrations in plasma. For the standard curves, we
used the second order (k = 2) polynomial regression
model (parabolic curve), Y = b0+b1X+b2X2....+bkXk, where
Y caret is the predicted outcome value for the polynomial
model with regression coefficients b1 to k for each degree
and y intercept b0. Quadruplicate determinations were
made, i.e., each sample was run in duplicate in two sepa-
rate assays.
Statistical Analysis
The cytokine measurements were not normally distrib-
uted. Since the sample sizes between control and test
groups were also different, the nonparametric Kruskal-Page 2 of 8
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determine the magnitudes of between-group differences.
Values of p < 0.05 were considered statistically significant.
The diagnostic accuracy of those cytokines significantly
different among cases and controls was analyzed by
receiver operating characteristics (ROC) curve analyses
[22] using the Statistical Package for Social Sciences
(SPSS) version 16 for Windows.
Results
We clustered the results of the cytokine assays into 5
groups according to the cytokine literature. The results of
the individual Kruskal-Wallis analyses are shown in Table
1.
Pro- inflammatory cytokines
A significant elevation in the relative amounts of 4 of 5
pro-inflammatory cytokines in peripheral blood plasma
of patients with CFS was found when compared with the
controls Only tumor necrosis factor (TNF)α was
unchanged. In cases, lymphotoxin (LT)α was elevated by
257% and IL-6 by 100% over the controls.
TH2 cytokines
Both interleukin (IL)-4 and IL-5 were elevated in CFS,
with the median of IL-4 240% and of IL-5 95% higher in
cases over controls.
Table 1: Cytokines in Plasma of Female CFS Patients Compared to Female Healthy Controls








TNFα Pro-inflammatory 7.3 (3.4 - 22.6) 6.4 (4.5 - 38.3) + 14 0.0 .949
LTα Pro-inflammatory 7.5 (4.5 - 38.3) 2.1 (4.5 - 12.4) + 257 20.4 .000
IL-6 Pro-inflammatory 6.4 (3.8 - 14.4) 3.2 (2.1 - 5.9) +100 15.1 .000
IL-1α Pro-inflammatory 3.2 (1.7 - 4.4) 2.3 (0.9 - 3.9) + 39 4.1 .044
IL-1β Pro-inflammatory 13.4 (4.5 - 38.3) 6.2 (4.2 - 38.3) + 100 4.2 .041
IFNγ TH1 3.1 (0.1 - 11.8) 2.6 (1.2 - 10.6) + 19 0.5 .467
IL-2 TH1 2.3 (1.4 - 5.4) 2.5 (2.1 - 3.5) - 8 0.6 .420
IL-12 TH1 4.4 (2.4 - 7.3) 2.0 (1.7 - 2.5) + 120 18.8 .000
IL-15 TH1 13.5 (7.0 - 23.6) 27.4 (19.7 - 49.4) - 51 15.0 .000
IL-17 TH17 3.8 (0.8 - 7.2) 2.9 (1.9 - 6.7) + 31 0.1 .785
IL-23 TH17 82.(70.3 - 113) 101.7 (45.0 - 375.6) - 16 0.8 .814
IL-4 TH2 1.7 (0.9 - 4.3) 0.5 (.03 - 1.1) + 240 20.7 .000
IL-5 TH2 7.4 (6.3 - 10.0) 3.8 (3.2 - 5.6) + 95 33.6 .000
IL-10 Anti-inflammatory 3.3 (2.1 - 5.6) 3.6 (2.2 - 6.4) - 9 0.1 .748
IL-13 Anti-inflammatory 1.7 (1.2 - 2.1) 2.0 (1.9 - 2.1) -15 9.6 .002
IL-8
(CXCL8)
NK cell attracting 9. (5.0 - 15.8) 15.4 (11.5 - 22.2) - 42 9.7 .002
a Values are expressed as medians. Values in parentheses are 25th and 75th percentiles.
b Cytokines determined as pg/ml.
c Percent differences were calculated by using the normal controls as a reference; the + or - sign indicates the direction of change.Page 3 of 8
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IL-13 was significantly lower (!5%) in CFS patients while
IL-10 was not different.
TH1 cytokines
Median plasma levels of IL-2 and IFNγ in CFS were similar
to those in controls. However, IL-12 was significantly ele-
vated (120%) and IL-15 decreased 15% in cases compared
to controls.
IL-8 (CXCL8)
This chemokine was 42% lower in the CFS patients.
TH17 cytokines
IL-17 and IL-23 were not significantly different in CFS
cases compared to controls.
ROC curve analyses
Results for those cytokines that were significantly higher
in the case/control comparison are shown in Figure 1 and
Table 2. Those for cytokines that were lower in CFS than
controls are shown in Figure 2 and Table 3. Area under the
curve (AUC) for IL-5 (0. 84), LTα (0.77), IL-4 (0.77), IL-
12 (0.76) indicated good biomarker potential. Coordi-
nates of the curves for these 4 cytokines are in Additional
File 1. The AUC of IL-6 (0.73), IL-15 (0.73), IL-8 (0.69),
IL-13 (0.68) IL-1α (0.62), IL-1β (0.62) showed fair poten-
tial as biomarkers (Tables 2 and 3).
Discussion
Several studies report cytokine abnormalities in CFS; how-
ever, the findings are mixed. Differences between reports
may be largely due to differences in methodologies [14].
Amounts of cytokines in plasma or serum are often below
the level of detection in traditional ELISA assays. In addi-
tion to assay sensitivity, results using the direct approach
are influenced by length of time following blood draw to
separation of serum or plasma, temperature of storage
and repeated thawing and freezing. In vitro stimulation
whole blood or peripheral blood mononuclear cells
(PBMC) is another approach to study cytokines. ELISA is
then used to measure cytokine content of supernatants of
culture fluids. Obviously, results depend on culture con-
ditions and stimulants used. Other techniques include
either in unstimulated or stimulated PBMC. Results
obtained with these methodologies are not directly com-
parable.
The availability of sensitive multiplex technology permit-
ted the determination of 16 cytokines simultaneously on
plasma samples from female CFS patients and age and
gender matched healthy controls. In the CFS cases, we
found an unusual pattern of the cytokines that define the
CD4 T cell. Dendritic cell derived IL-12, the main TH1-
inducing cytokine leading to production of IFNγ, IL-2 and
TNFα, was elevated. However, IFNγ, IL-2 and TNFα were
unchanged in plasma of CFS cases compared to controls.
Another dendritic cell derived cytokine, IL-15, was
decreased. IL-2 and IL-15 are key participants in CD8 T
cell and NK cell activation and function. Sharing the beta
and gamma receptor subunits results in several common
functions: e.g. cytotoxicity. On the other hand, due to
their distinct alpha receptor subunits, they play opposing
roles in immune processes such as activation induced cell
death (IL-2) and immunological memory (IL-15) [23]. IL-
23 (unchanged between controls and cases) stimulates
the differentiation and function of the TH17 subset of
CD4 T cells, a relatively newly described immune defense.
The TH17 CD4 cell produces IL-17, protects surfaces (e.g.,
skin, lining of the intestine) against bacteria, and plays a
critical role in chronic intestinal inflammation [24,25].
The unchanged IL-17 and IL-23 levels in CFS noted in this
study would argue against bacterial gastrointestinal infec-
tions as playing an important role in persistent illness.
Along with the TH1 abnormalities, we found up regula-
tion of TH2 associated cytokines, IL-4 and IL-5, in the CFS
subjects. Allergy is common in CFS cases. Years ago, Straus
et al, reported >50% atopy in 24 CFS patients [26]. The
elevation of these two cytokines implies a type 2 shift -
and diminished stimulus for cytotoxic lymphocyte func-
tion.
Table 2: AUC for Plasma Cytokines Significantly Higher in CFS Cases vs. Controls
Cytokines Area Std. Errora Asymptotic Sig.b Asymptotic 95% Confidence Interval
Lower Boundary Upper Boundary
LTα .769 .049 .000 .673 .865
IL-6 .731 .050 .000 .633 .828
IL-1α .620 .056 .044 .509 .730
IL-1 β .621 .062 .041 .499 .744
IL-5 .844 .041 .000 .764 .925
IL-4 .770 .048 .000 .676 .864
IL-12 .758 .054 .000 .653 .863
a Under the nonparametric assumption
b Null hypothesis: true area = 0.5Page 4 of 8
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supported by the elevation of four members of the pro-
inflammatory cytokine cascade [27], LTα, IL-1α, IL-1β,
and IL-6, in the CFS samples compared to controls. The
exception was TNFα, although the median value for cases
was 14% higher than controls and about 1/4 of CFS
patients in other studies had elevated TNFα [15,17]. Inter-
leukin-13, associated with inhibitory effects on inflamma-
tory cytokine production, was lower in cases compared to
controls. The anti-inflammatory cytokine, IL10, was not
different. The inflammatory mediator IL-8 (a chemokine
known as CXCL8) known to be responsible for the migra-
tion and activation of neutrophils and NK cells [28] was
decreased in plasma of CFS patients.
The observations of abnormal cytokine patterns in CFS
patients support the reports of retrovirus infections and
reactivation of latent herpes virus infections. DeFreitas, et
al found HTLV-II- like gag sequences by polymerase chain
reaction and in situ hybridization as well as antibodies
reactive with human T- lymphotropic virus (HTLV) in a
majority of 30 CFS cases. Twenty healthy controls were
negative for the three assays [11]. Holmes, et al, reported
that structures consistent with stages of a Lentivirus repli-
cative cycle were observed by electron microscopy in 12-
day PBMC cultures from 10 of 17 CFS patients and not in
controls [12]. Recently, DNA from a human gammaretro-
virus, xenotropic murine leukemia virus-related virus
(XMRV), was found in the PBMC of 68 of 101 patients
compared to 8 of 218 healthy controls. Patient-derived,
activated PBMC produced infectious XMRV in vitro. Both
cell associated and cell-free transmission of the virus to
Table 3: AUC for Plasma Cytokines Significantly Lower in CFS Cases vs. Controls
Cytokines Area Std. Errora Asymptotic Sig.b Asymptotic 95% Confidence Interval
Lower Boundary Upper Boundary
IL-8 .685 .062 .002 .564 .806
IL-15 .731 .056 .000 .620 .841
IL-13 .682 .064 .002 .556 .808
a Under the nonparametric assumption
b Null hypothesis: true area = 0.5
ROC curves shows the classification performance of plasma cytokines from CFS cases and healthy controlsFigure 1
ROC curves shows the classification performance of 
plasma cytokines from CFS cases and healthy con-
trols. Curves are for the 7 cytokines significantly elevated (p 
< .05) in cases compared to controls (IL-4, IL-5, IL-12, LTα, 
IL-1α, IL-1β, and IL-6).
ROC curves show the classification performance of plasma cytokines from CFS cases and healthy controlsFigure 2
ROC curves show the classification performance of 
plasma cytokines from CFS cases and healthy con-
trols. Curves are for the 3 cytokines significantly lower (p < 
.05) in cases compared to controls (IL-8, IL-13 and IL-15).Page 5 of 8
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was possible [13]. The XMRV gag and env sequences dis-
covered in CFS cases were more than 99% similar to those
previously reported for prostate tumor-associated strains
of XMRV [29].
Latent herpes virus infections are likely to be important in
CFS. Immunologic effects of persistent herpetic infections
do not require of virus DNA synthesis. For example,
Glazer and colleagues [9] reported that EBV encoded
deoxyuridine triphosphate nucleotidohydrolase (dUT-
Pase) upregulated the production of proinflammatory
cytokines, including IL-1β and IL-6. Also, dUTPase
administered to mice, produced sickness behaviors
known to be induced by some of the cytokines we showed
to be upregulated. A subsequent paper showed that EBV-
encoded dUTPase can enhance production of proinflam-
matory cytokines by monocytes/macrophages in contact
with endothelial cells of blood vessels [30]. In addition,
Ariza, et al demonstrated that the purified EBV-encoded
dUTPase activated NFkappaB in a dose-dependent
through Toll Like Receptor 2 (TLR2). Treatment of human
monocyte-derived macrophages with an anti-EBV-
encoded dUTPase or with an anti-TLR2 blocked the pro-
duction of IL-6 [31]. Iwakiri, et al reported that EBV-
encoded small RNA (EBER), which is released from EBV-
infected cells, was responsible for immune activation by
EBV, including release of proinflammatory cytokines [32].
A recent study (M Vera, MA Fletcher, C Cuba, L Garcia, N
Klimas, presented to the International Association for
Chronic Fatigue Syndrome/Myalgic Encephalitis, Reno,
NV, March, 2009) reported that the anti-viral and
immuno-modulatory drug, inosine pranobex, led to sig-
nificant improvement in the clinical scores of 61 patients
treated for 6 months. Immune activation was decreased,
NK cell activity was improved and titers of anti-Epstein
Barr Virus Viral Capsid Antigen IgG were significant
decreased. Antibody titers to Human Herpes Virus 6 were
unchanged. A larger randomized trial would seem appro-
priate.
According to ROC analysis, plasma IL-5 was best at distin-
guishing CFS cases from controls, with the highest per-
centage difference from the median of normal and the
largest AUC. We recently reported elevation of IL-5 in the
supernatants of mitogen-stimulated cultured lym-
phocytes from Gulf War Illness (GWI) cases compared to
controls [33]. The symptoms of GWI are similar to those
reported in CFS. Three other cytokines with AUC values
consistent with good potential as biomarkers were LTα,
IL-4 and IL-12. Less promising as systemic markers of CFS,
but with AUC significantly different in cases compared to
controls, were IL-6, IL-15, IL-13, IL-1α and IL-1β.
The cytokine changes observed between CFS patients and
healthy, matched controls are likely to be indicative of
immune activation and inflammation. Fibromyalgia,
GWI, rheumatologic disorders and multiple sclerosis may
have similar cytokine patterns. Future research will be
required to determine if the cytokine patterns associated
with CFS cases are similar or distinct from other complex,
chronic and poorly understood illnesses.
Obvious limitations of this study are that the samples rep-
resent a single point in time and a single gender. The par-
ent protocol, from which the CFS samples were gathered,
is a larger longitudinal study. Subjects are followed over
18 months and sample collection includes times of rela-
tive symptom remission or exacerbation. Completion of
the study will allow the correlation of CFS related symp-
toms and other immune markers with the cytokine pat-
terns. CFS is a condition that affects women in
disproportionate numbers. The larger study will have suf-
ficient power to allow the study of cytokine patterns in
men with CFS. As Broderick and colleagues have pointed
out, markers of immune status tend to be highly variable
and context-specific leading to inconsistent biomarker
lists [34]. These indicators are parts of a complex and inte-
grated system and their inter-dependency must be
addressed. Accordingly, we are currently engaged in com-
bining the proteomic and genomic data on cytokines with
other immunologic and neuroendocrine markers, both
proteomic and genomic, in order to map the network
structure of neuroendocrine-immune interaction in CFS.
We will focus on identifying associations between nodes
that are differentially expressed across disease group and
controls.
The finding of cytokine imbalances in the peripheral
blood compartment has implications for physiological
and psychological function changes. The decreased natu-
ral killer (NK) cell cytotoxic and lymphoproliferative
activities and increased allergic and autoimmune manifes-
tations in CFS would be compatible with the hypothesis
that the immune system of affected individuals is biased
towards a T- helper (TH) 2 type, or humoral immunity-ori-
ented cytokine pattern. The elevations in LTα, IL-1α, IL1β
and IL-6 indicate inflammation, likely to be accompanied
by autoantibody production, inappropriate fatigue, myal-
gia and arthralgia, as well as changes in mood and sleep
patterns.
Conclusion
This is study is among the first in the CFS literature to
report the plasma profiles of a reasonably large panel of
cytokines assessed simultaneously by multiplex tech-
nique. Cytokine abnormalities appear to be common in
CFS. Several showed promise as potential biomarkers. The
changes from the normal condition indicate immune acti-Page 6 of 8
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peutic strategies. The results imply a disorganized
regulatory pattern of TH1 function, critical to antiviral
defense. The data from this study support a TH2 shift, pro-
inflammatory cytokine up regulation and down regula-
tion of important mediators of cytotoxic cell function.
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